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Abstract 12 
 13 
Objective To evaluate the propofol requirement, cardiovascular and respiratory variables 14 
using midazolam or lidocaine with a propofol target-controlled infusion (PTCI) for 15 
induction of anaesthesia in healthy dogs. 16 
Study design Prospective, randomized, controlled blinded clinical trial. 17 
Animals Sixty client-owned dogs [American Society of Anesthesiologists (ASA) I–II] 18 
undergoing surgical procedures. 19 
Methods Thirty minutes after premedication with acepromazine (0.03 mg kg-1) and 20 
morphine (0.2 mg kg-1), PTCI was started and maintained at a plasma target concentration 21 
of 1 µg mL-1. Three minutes later, dogs (n = 20 per group) received either 5 mL 0.9% 22 
sodium chloride (SG), 2 mg kg–1 of lidocaine (LG) or 0.2 mg kg–1 of midazolam (MG) 23 
intravenously (IV) as a co-induction agent. Two minutes later, suitability for endotracheal 24 
intubation was assessed. If intubation was not possible, the propofol target was increased 25 
by 0.5 µg mL–1 every 60 seconds until it was successfully achieved. Heart rate (HR), 26 
respiratory rate (fR), and oscillometric systolic arterial pressure (SAP), mean arterial 27 
pressure (MAP) and diastolic arterial pressure (DAP) were recorded immediately prior to 28 
commencing PTCI (B0), prior to intubation (BI), immediately after (T0), and at 3 (T3) and 29 
5 (T5) minutes post-intubation. End-tidal partial pressures of carbon dioxide (PE´CO2) were 30 
recorded at T0, T3 and T5. The occurrence of excitement at any time point was noted. 31 
Results The median (range) propofol target concentration for endotracheal intubation was 32 
significantly lower in MG, 1.5 (1.0 - 4.0) µg mL-1 compared with LG, 2.5 (1.5 - 4.5) 33 
µg mL-1 or SG, 3.0 (2.0 - 5.0) µg mL-1. Heart rate, MAP, fR and PE´CO2 were similar in the 34 
three groups at all time points. No excitement was reported in any dog. 35 
Conclusions and clinical relevance Midazolam, but not lidocaine, provided a significant 36 
reduction in PTCI requirement for induction of anaesthesia thereby allowing successful 37 
intubation. However, cardiovascular and respiratory effects were not different between the 38 
groups. 39 
Keywords  co-induction, lidocaine, midazolam, propofol, target-controlled infusion. 40 
 41 
Introduction 42 
Propofol is widely used for induction of general anaesthesia in dogs but commonly 43 
produces both cardiovascular and respiratory depression (Nakaigawa et al. 1995; Muir & 44 
Gadawski 1998). While the latter can be managed using intermittent positive pressure 45 
ventilation, the cardiovascular effects, primarily vasodilatation at the usual clinical doses, 46 
are more clinically challenging (Goodchild & Serrao 1989). Although these effects are 47 
generally well tolerated by healthy dogs, those with any degree of pre-existing 48 
cardiovascular compromise may be unable to compensate for these changes.  49 
Propofol target-controlled infusion (PTCI) has been used for induction and maintenance of 50 
anaesthesia in dogs (Beths et al. 2001; Musk et al. 2005). This technique employs a 51 
software-controlled syringe pump that delivers propofol as a variable rate infusion to 52 
achieve and maintain a user-selected plasma target concentration, which is	 based on 53 
population pharmacokinetic parameters and patient factors including body weight. The 54 
predicted plasma target concentration of propofol for induction of general anaesthesia in 55 
dogs ranges from 3 to 6 µg mL-1 (Beths et al. 2001; Musk et al. 2005; Beier et al. 2009). 56 
This range is similar to that reported in man (White & Kenny 1990). One recognized 57 
benefit of PTCI for induction of anaesthesia is that this technique allows a gradual increase 58 
in the plasma concentration as compared with manually controlled infusion techniques 59 
(Struys et al. 1997). This may potentially result in less cardiovascular depression (Stokes & 60 
Hutton 1991).  61 
Using a ‘co-induction’ technique can also potentially lessen the cardiovascular-depressant 62 
effects of propofol. Co-induction refers to the administration of a sedative, anaesthetic or 63 
analgesic drug along with the main hypnotic agent to reduce the dose of induction agent 64 
required (Armein et al. 1995). To achieve a beneficial effect from co-induction, the drug 65 
selected should not only have a hypnotic dose-sparing action but must have minimal 66 
cardiovascular depressant effects of its own.  67 
In human anaesthesia, the use of midazolam as a co-induction agent with propofol is well 68 
documented but the results in studies have been conflicting. Oxorn et al. (1997) did not 69 
observe any significant effect of midazolam on the propofol requirement whereas others 70 
have demonstrated an approximate 50% reduction in propofol dose for induction of 71 
anaesthesia if midazolam is given up to 10 minutes prior to propofol administration (Short 72 
& Chui 1991; Ong et al. 2000). Premedication with midazolam also increased the number 73 
of human patients achieving successful induction of general anaesthesia with a fixed low 74 
target of PTCI without major cardiovascular effects (Tzabar et al. 1996). In dogs, however, 75 
midazolam administered as an intramuscular (IM) premedication or intravenous (IV) co-76 
induction agent, at doses of 0.1 and 0.2 mg kg–1 respectively, resulted in excitement and 77 
only a mild reduction in propofol requirement for induction of anaesthesia (Stegmann & 78 
Bester 2001; Covey-Crump & Murison 2008; Hopkins et al. 2014). These outcomes can be 79 
improved if midazolam is administered soon after a sub-hypnotic bolus of propofol 80 
(Sanchez et al. 2013). Currently, there are no published reports of the effects of midazolam 81 
on either the plasma propofol target required or its cardiovascular and respiratory effects 82 
when used as a co-induction agent with PTCI in dogs.  83 
In man, co-induction with lidocaine results in a lower dose requirement of propofol for 84 
induction of anaesthesia thus limiting the associated cardiovascular depression (Senturk et 85 
al. 2002; Kelsaka et al. 2011; Yang et al. 2013). In contrast, in dogs, there does not appear 86 
to be a sparing effect when lidocaine is administered immediately prior to propofol 87 
induction of anaesthesia (Braun et al. 2007). The effects of co-induction with lidocaine on 88 
PTCI in dogs, however, have not been investigated. 89 
The aims of the present study were to evaluate if co-induction with midazolam or lidocaine 90 
could reduce the requirement of PTCI in healthy dogs for induction of general anaesthesia, 91 
and to investigate the effects of each drug combination on cardio-respiratory variables.  92 
 93 
Materials and methods 94 
The present clinical study was approved by the Ethics Committee of the School of 95 
Veterinary Medicine, University of Glasgow. The Veterinary Medicines Directorate 96 
approved the use of morphine, lidocaine and midazolam. Informed client consent was not 97 
obtained because the present study was started prior to becoming a requirement for 98 
publication. 99 
Animals 100 
Sixty client-owned dogs of various breeds, scheduled for elective surgical procedures at the 101 
Small Animal Hospital, University of Glasgow, were enrolled in the study.  102 
The dogs were considered eligible for inclusion if categorized as American Society of 103 
Anesthesiologists (ASA) physical status I or II, based on history and physical examination. 104 
Haematology and serum biochemistry were carried out in some but not all dogs depending 105 
on the preference of the individual clinician referring the dog for anaesthesia. Dogs were 106 
not considered eligible if brachycephalic, significantly overweight, younger than 6 months 107 
or older than 8 years of age, receiving opioid analgesic medication or with a history of 108 
vomiting/regurgitation or respiratory obstruction. 109 
Study protocol 110 
For the purpose of the study, dogs were randomly assigned to one of three groups prior to 111 
premedication (n = 20 for each group) using a computer-generated random numbers list: 112 
saline group (SG), lidocaine group (LG) and midazolam group (MG). Dogs in SG received 113 
a total volume of 5 mL of 0.9% sodium chloride (Vetivex; Dechra Veterinary Products, 114 
UK) IV. Dogs in LG received 2 mg kg-1 of lidocaine 2% (Lidocaine hydrochloride injection 115 
2%; Hameln Pharmaceuticals Ltd, UK) IV whereas those in MG received 0.2 mg kg-1 of 116 
midazolam (Hypnovel, 10 mg 2 mL-1; Roche Products Ltd, UK) IV. In the last two groups, 117 
the co-induction drug was diluted to a total volume of 5 mL with 0.9% sodium chloride to 118 
facilitate blinding.  119 
Food, but not water, was withheld for 8 to 12 hours prior to premedication. Premedication 120 
was carried out using acepromazine (ACP Injection 2 mg mL-1; Novartis Animal Health 121 
Ltd, UK), 0.03 mg kg–1 up to a maximum of 1 mg, and morphine (Morphine Sulphate 122 
injection, 10 mg mL–1; Martindale Pharmaceuticals, UK), 0.2 mg kg-1, mixed in the same 123 
syringe and injected IM into the epaxial muscles of the neck. Thirty minutes after 124 
administration of premedication, the level of sedation was scored (Appendix 1) and the 125 
dogs were moved into a quiet induction room to minimize stimulation throughout the study 126 
period. An intravenous cannula (Biovalve PTFE; Vygon, France) was placed into a 127 
cephalic vein. 128 
Dogs were positioned in sternal recumbency for the entire duration of the data collection 129 
and connected to an electrocardiograph (Mindray PM-8000Vet, Shenzhen Mindray Bio-130 
Medical Electronics Co, Ltd, China) and an oscillometric blood pressure monitor (Cardell 131 
Veterinary Monitor 9401 BP, Sharn Veterinary Inc., FL, USA).  132 
Pre-oxygenation via a facemask connected to a coaxial Bain breathing system (Intersurgical 133 
Ltd, UK) was commenced at a flow rate of 200 mL kg–1 minute–1 for at least 3 minutes 134 
before induction of general anaesthesia and was continued until successful intubation. 135 
Propofol TCI was administered via a syringe driver (Graseby 3500 Anaesthesia Pump; 136 
SIMS Graseby Ltd, UK) incorporating a ‘PK-Fusor for propofol 10 mg mL–1 in dogs’ 137 
software. The age and body weight of the dog were entered into the device, and a propofol 138 
plasma target concentration of 1 µg mL–1 was selected. Propofol TCI was then started. At 139 
3 minutes after attainment of the plasma target concentration, the co-induction drug 140 
(midazolam, lidocaine or saline) was administered IV over 30 seconds. Any reaction, for 141 
example, patient excitement, was noted. Two minutes later, the dog was assessed to 142 
determine if endotracheal intubation was possible by checking pre-established end points: 143 
weakened palpebral reflex, rostromedial rotation of the eyeball, a reduction in jaw tone and 144 
lack of tongue withdrawal. When these conditions were obtained, endotracheal intubation 145 
was attempted. If these criteria were not met, the propofol plasma target concentration was 146 
increased in a stepwise manner by 0.5 µg mL–1 each 60 seconds, reassessing the dog at 147 
each new target until successful endotracheal intubation was achieved. The required 148 
propofol target concentration was recorded.  149 
Heart rate, fR, SAP, MAP and DAP were recorded just prior to commencing PTCI (B0), 150 
prior to intubation (BI), immediately after (T0), and at 3 (T3) and 5 (T5) minutes post-151 
endotracheal intubation. To measure the blood pressure, an inflatable cuff was applied to 152 
the base of the tail, using a cuff width of approximately 40% of the circumference. The 153 
blood pressure was measured four times: the first measurement was discarded and the 154 
following three measurements were averaged to maximize the accuracy of the readings. 155 
The end-tidal partial pressure of CO2 (PE’CO2) (Nellcor NPB-70; Mallinckrodt, 156 
Netherland), and arterial haemoglobin oxygen saturation (SpO2) (Nonin Model 9847V; 157 
Nonin Medial, Inc., MN, USA) were also recorded immediately after (T0), and at 3 (T3) 158 
and at 5 (T5) minutes post-intubation. If post-induction apnoea (defined as the absence of 159 
spontaneous respiratory effort for at least 60 seconds) occurred, manual ventilation at a rate 160 
of 2 breaths per minute was initiated until spontaneous ventilation resumed. The adjustable 161 
pressure-limiting valve of the Bain breathing system was closed and the rebreathing bag 162 
was manually squeezed to achieve a maximum peak inspiratory pressure of 20 cmH2O 163 
during inspiration. 164 
Once the data collection was completed, the PTCI was discontinued and general 165 
anaesthesia was maintained according to the requirement of the procedure the dog was 166 
undergoing. 167 
Statistical analysis 168 
Power analysis, based on data derived from a pilot study with 18 dogs in total, indicated 169 
that a sample size of at least 18 dogs per group would detect a clinically significant 170 
difference of 0.5 µg mL-1 for the predicted plasma target concentration of propofol for 171 
induction of anaesthesia with a power of 80%.  172 
Variables were checked for normality by examining box plots and histograms. Either the 173 
mean or median values were used for statistical comparison of data between the groups. 174 
Propofol target concentration data were analysed using Kruskal–Wallis and post-hoc 175 
Mann–Whitney tests. The age, body weight, HR, MAP, fR, PE’CO2 and SpO2 were analysed 176 
using t-tests and repeated measures analysis of variance (one-way and within a general 177 
linear model framework). Chi-squared tests were used to examine the association between 178 
categorical variables (sedation score, sex). All analyses were performed using Minitab 16 179 
(Minitab Inc., UK). A p-value of < 0.05 was considered statistically significant. 180 
Results 181 
Demographics 182 
Of the 60 dogs included in the study, 29 were male and 31 female, with a mean age of 183 
48 ± 27 months and a mean body weight of 29 ± 9.7 kg. There were no differences between 184 
the three groups with respect to age, body weight or sedation score after premedication. 185 
Plasma target concentration of propofol 186 
The median (range) values of the plasma target concentrations of propofol for induction of 187 
anaesthesia were 1.5 (1.0–4.0) µg mL-1, 2.5 (1.5–4.5) µg mL-1 and 3.0 (2.0–5.0) µg mL-1 in 188 
MG, LG and SG, respectively (Fig. 1). The propofol target concentration was statistically 189 
significantly lower in MG compared with LG (p = 0.0022) and SG (p = 0.0001). No 190 
significant difference in the propofol requirement was observed between LG and SG. The 191 
sedation score after premedication did not affect the target concentration of propofol 192 
required for successful intubation. 193 
Cardiovascular variables  194 
In the three groups, HR increased before intubation (BI) and after intubation (T0) compared 195 
with B0 values and decreased at 3 (T3) and 5 minutes (T5) after intubation (Fig. 2a). The 196 
HR was significantly affected by time (p < 0.001) and subject variability (p < 0.001) but 197 
not by the co-induction agent. There was no significant difference in the change in HR after 198 
intubation (T0) compared with before intubation (BI) between the three groups. The mean 199 
change in HR (95% CI) after intubation was +11.0 beats minute-1 (6.7 to 15.5) in MG, +7.8 200 
beats minute-1 (0.2 to 15.4) in LG and +5.0 beats minute-1 (–0.2 to 10.3) in SG. 201 
In the three groups, the MAP increased before (BI) and after intubation (T0) compared with 202 
B0 values and decreased at 3 (T3) and 5 minutes (T5) after intubation (Fig. 2b). The mean 203 
arterial pressure was significantly affected by time (p = 0.008) and subject variability 204 
(p < 0.001) but not by the co-induction agent. There was no significant difference in the 205 
change in MAP after intubation (T0) compared with before intubation (BI) between the 206 
three groups. The mean change in MAP (95% CI) after intubation was +1.0 mmHg (–3.1 to 207 
5.2) in MG, +6.0 mmHg (0.5 to 11.4) in LG and +2.3 mmHg (–1.7 to 6.2) in SG. 208 
Respiratory variables 209 
The respiratory rate was similar in the three groups at all time points. Values were lower 210 
after intubation (T0) and increased by the end of the data collection (T5) in all groups. Post-211 
induction apnoea was not observed in any of the dogs. The values of PE’CO2 were similar in 212 
the three groups at all time points. Recorded values were lower after intubation (T0) and 213 
increased by the end of the data collection (T5) in all groups (Table 1). 214 
In all dogs, SpO2 was always equal or greater than 98% at all time points. Values were 215 
similar in the three groups at all time points. 216 
 217 
Discussion 218 
The present study demonstrated that only co-induction with midazolam was associated with 219 
a significantly lower propofol plasma target concentration for successful endotracheal 220 
intubation in healthy dogs. In addition, the median target in dogs in the saline group agreed 221 
with previously reported findings for a similar premedication protocol but with a PTCI as 222 
the sole induction agent (Beths et al. 2001; Musk et al. 2005).  223 
Propofol exerts its anaesthetic-hypnotic effect by potentiating GABAA receptor activity in 224 
the brain and spinal cord (Sanna et al. 1995). Gamma-aminobutyric acid (GABA) is the 225 
principal inhibitory neurotransmitter in the central nervous system. Midazolam also 226 
enhances the affinity of GABAA receptors for GABA (Jensen & Lambert 1986); therefore, 227 
when midazolam is combined with propofol as premedication or as a co-induction agent, a 228 
synergistic interaction for hypnosis and immobility would be anticipated. This has been 229 
demonstrated in various studies in man where patients receiving midazolam as a co-230 
induction agent required lower propofol doses for induction of anaesthesia (Short & Chui 231 
1991; Wilder-Smith et al. 2001). Such an effect has not been seen in previous studies in 232 
dogs, where a high incidence of acute behavioural changes including excitement has been 233 
noted when midazolam was used either for premedication or as a co-induction agent with 234 
propofol (Stegmann & Bester 2001; Covey-Crump & Murison 2008). These behavioural 235 
changes may have affected subsequent propofol requirements, potentially offsetting any 236 
hypnotic-sparing effect midazolam may produce in the absence of excitation. Covey-237 
Crump and Murison (2008) reported no decrease in the required propofol dose when 238 
assessing midazolam co-induction. However, they reported results for the midazolam group 239 
as a whole and did not look specifically at the propofol requirement relative to the 240 
individual animal’s level of excitement.  241 
Paradoxical excitation is rarely reported in man and its origin is unclear. One theory states 242 
that the inhibitory action of benzodiazepines may cause a loss of cortical restraint in some 243 
patients, leading to excitement (Paton 2002). Other authors hypothesize that it may be 244 
correlated with central cholinergic effects, as it can be partially antagonized with 245 
cholinesterase inhibitors such as physostigmine (Di Liberti et al. 1975). The serotonergic 246 
system may also be involved when aggressive behaviour occurs (Senninger & Laxenaire 247 
1995). In the present study, it was hypothesized that by administering a sub-hypnotic dose 248 
of propofol at a plasma target concentration of 1µg mL-1 prior to administering midazolam, 249 
we could potentially avoid any unwanted excitatory effects and achieve a reduction in the 250 
total propofol requirements for induction of anaesthesia. This was confirmed by our results, 251 
in that no dog exhibited excitement after administration of the co-induction drugs, and 252 
significant propofol-sparing effects were demonstrated for midazolam. Similar findings 253 
have been reported in recently published canine studies where administration of a small 254 
bolus dose of propofol prior to midazolam co-induction resulted in a reduced propofol 255 
requirement for induction of anaesthesia; however, the excitatory effects, although reduced, 256 
were not eliminated completely using this technique (Sanchez et al. 2013; Robinson & 257 
Borer-Weir 2013; Hopkins et al. 2014). In this present study, we demonstrated the effect of 258 
midazolam in reducing the propofol target concentration required for induction of 259 
anaesthesia in dogs, when a TCI system was used, and the ability of this technique to 260 
minimize the incidence of any excitatory effects.  261 
Unlike midazolam, lidocaine did not reduce propofol requirements for induction of 262 
anaesthesia in the present study, which is in agreement with the findings of Braun et al. 263 
(2007). The absence of a propofol-sparing effect of lidocaine in dogs is perhaps surprising 264 
because a reduction in the isoflurane and sevoflurane minimum alveolar concentration is 265 
demonstrated in this species when lidocaine is given as a constant rate infusion with inhaled 266 
anaesthetic agents (Muir et al. 2003; Valverde et al. 2004; Matsubara et al. 2009). In man, 267 
in contrast, IV or IM administration of lidocaine reduces the induction dose of propofol 268 
(Senturk et al. 2002; Kelsaka et al. 2011). In addition, humans receiving PTCI with a 269 
lidocaine infusion for maintenance of general anaesthesia had a reduction in the bi-spectral 270 
index-guided requirements for propofol was but this effect was only observed during 271 
surgical stimulation (Hans et al. 2010). As lidocaine has anti-nociceptive properties, it may 272 
produce anaesthetic sparing effects only during noxious stimulation. This could explain 273 
why no reduction in the propofol target was observed with lidocaine co-induction in the 274 
present study.  275 
In the present study, the cardiovascular variables (the mean HR and MAP) were similar 276 
between the three groups of dogs at all time points. Induction of anaesthesia with high 277 
doses of propofol generally produces vasodilatation and direct myocardial depression in 278 
dogs (Ismail et al. 1992). However, despite the resulting decrease in cardiac output and 279 
arterial blood pressure, propofol anaesthesia is classically characterized by a relatively low 280 
HR when compared with other hypnotics, such as thiopentone or alfaxalone (Quandt et al. 281 
1998; Amengual et al. 2013). This effect has been explained by two different mechanisms. 282 
First, there is a central effect of ‘resetting’ the baroreflex response through vagotonic and/or 283 
sympatholytic effects of the drug (Cullen et al. 1987; Samain et al. 1989) and second a 284 
peripheral effect of inhibition of the sympathetic nervous activity and decreased baroreflex 285 
sensitivity (Sellgren et al. 1994, Chen et al. 2011).  286 
Midazolam often causes a rise in HR in dogs when used as a co-induction agent in 287 
conjunction with propofol (Covey-Crump & Murison 2008; Sanchez et al. 2013; Hopkins 288 
et al. 2014). This increase in HR may occur as a result of excitation (Stegmann & Bester 289 
2001); however, Sanchez et al. (2013) reported that, a sub-anaesthetic dose of propofol 290 
given prior to midazolam reduced the incidence of paradoxical excitation but did not 291 
prevent an increase in HR, making this cardiovascular effect more complex to explain fully. 292 
In man, when midazolam is used in a similar manner, as a co-induction agent with 293 
propofol, an increase in HR also occurs when compared with the use of propofol alone. 294 
This is explained by the sparing effect of midazolam on propofol induction dose preserving 295 
baroreflex activity in response to a decrease in blood pressure (Win et al. 2007). The 296 
changes in HR and MAP observed in the midazolam group, in this study were no different 297 
to those seen in the saline group. Midazolam is generally considered to have minimal 298 
effects on cardiovascular function; however, at the dose used in the present study, slight 299 
vasodilatation may occur in dogs (Jones et al. 1979). Although midazolam significantly 300 
decreased propofol induction requirements, it did not produce any greater preservation of 301 
MAP than propofol alone. This may suggest that midazolam itself contributed to a decrease 302 
in MAP and, therefore, there would appear to be no valid reason to consider midazolam a 303 
suitable co-induction agent with propofol in healthy dogs.  304 
Similar to midazolam, lidocaine co-induction did not produce cardiovascular effects that 305 
differed from propofol alone, with no significant differences in the mean HR or MAP at 306 
any time point between dogs in the LG and SG groups. Laryngoscopy, stimulation of the 307 
upper airways and endotracheal intubation are associated with haemodynamic changes that 308 
can result in increased HR and MAP (Halevy et al. 2003). In humans, IV lidocaine has been 309 
shown to blunt this response (Qi et al. 2013); consequently, it might be anticipated that HR 310 
and MAP would have been lower in LG compared with SG dogs after endotracheal 311 
intubation but this was not observed. This would suggest that lidocaine does not obtund the 312 
pressor response to endotracheal intubation in dogs to the same extent as it does in humans. 313 
A previous study similarly demonstrated no benefit on SAP and HR variables in dogs when 314 
lidocaine was injected just prior to propofol induction (Jolliffe et al. 2007). It was also 315 
possible, however, that any pressor response to intubation in the dogs in the present study 316 
was too transient to be detected by an oscillometric blood pressure system. These findings 317 
may support that administration of propofol to effect using a PTCI is already a technique 318 
with clinically acceptable haemodynamic stability.  319 
In the present study, the mean fR and PE’CO2 were similar in the three groups at all time 320 
points and none of the dogs developed post-induction apnoea (PIA). A rapid manual bolus 321 
injection of propofol for induction of anaesthesia can cause respiratory depression and 322 
apnoea in healthy dogs (Muir & Gadawski 1993; Amengual et al. 2013). Previous studies 323 
have demonstrated a high incidence of PIA depending on the speed of administration of the 324 
drug. A rate of occurrence of PIA of 75% occurred when propofol was injected over 30–60 325 
seconds (Bufalari et al. 1997) and 60% when propofol was administered over 20–30 326 
seconds (Murison 2001). Musk et al. (2005) showed that the incidence of PIA could be 327 
reduced to 30–45% when propofol is administered slowly by TCI. In this study, our PTCI 328 
technique eliminated the occurrence of PIA. This may have been the result of a slow 329 
incremental increase of a propofol target concentration and repeated assessment of 330 
suitability for intubation. The use of midazolam as a co-induction agent did not increase the 331 
incidence of PIA. This is in contrast to other studies where PIA appeared to be a problem in 332 
any of the groups (Covey-Crump & Murison 2008; Sanchez et al. 2013; Hopkins et al. 333 
2014).  334 
There are some limitations of this present study. First, all of the dogs were healthy patients 335 
undergoing elective procedures. Co-induction techniques may be more beneficial in non-336 
healthy dogs such as those with a degree of pre-existing cardiovascular compromise. In 337 
addition, the use of non-invasive arterial blood pressure monitoring may not be accurate in 338 
detecting rapid changes in blood pressure. Given that this was a clinical study, it would not 339 
have been possible from an ethical point of view to perform an invasive monitoring 340 
technique, given the ASA physical status of the dogs and procedures being undertaken.  341 
 342 
Conclusions 343 
Co-induction with midazolam, but not lidocaine, reduced the propofol requirements for 344 
endotracheal intubation in healthy dogs when using a TCI system. Despite a significant 345 
reduction in propofol plasma target concentration in the midazolam group, no 346 
haemodynamic benefits were observed after endotracheal intubation. However, further 347 
studies are needed to evaluate the effects of this co-induction technique in non-healthy 348 
dogs.  349 
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